Nabriva Therapeutics Archives

Nabriva story bacterial pneumonia antibiotic

News and Trends 20 Aug 2019

Nabriva Therapeutics Gets FDA Green Light for Pneumonia Antibiotic

The US FDA has approved Nabriva Therapeutics’ Xenleta for treating community-acquired bacterial pneumonia, the first in a new class of antibiotics developed to treat this condition. Xenleta, also known as lefamulin, was discovered almost 10 years ago by Nabriva Therapeutics, a spinout company from Novartis split between Austria, Ireland and the US. The approval is […]

August 20, 2019 - 3 minutesmins - By Helen Albert

Nabriva Therapeutics Pneumonia Antibiotic

News and Trends 23 May 2018

Another Pneumonia Antibiotic is Close to Treating Patients

Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […]

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 13 Nov 2017

World Antibiotic Awareness Week: Here are Biotech’s Top 5 Strategies to Overcome Resistance

This week marks the WHO’s World Antibiotic Awareness Week. We had a look at some of the best work being done by biotechs to fight resistance. An estimated 154 million prescriptions for antibiotics are written each year, but up to 30% are unnecessary. The World Health Organization has set up World Antibiotic Awareness Week to tackle this. This year’s theme is […]

November 13, 2017 - 3 minutesmins - By Alex Dale

More News! 18 Sep 2017

Austrian Biotech Scores a Phase III Win in the Fight Against Antibiotic Resistance

The novel antibiotic lefamulin brought home late-stage success to Nabriva by proving itself to be on par with the standard treatment in pneumonia. Novartis spinout Nabriva has been developing antibiotics since 2006 and now boasts over 150 employees and a $285M (€239M) market cap. The company just reported that its latest stage program, centered on lefamulin for […]

September 18, 2017 - 1 minutemin - By Evelyn Warner

David Chiswell interview Kymab Antibodies

Interview 18 Sep 2017

David Chiswell: “We are getting close to the best way of making antibodies”

We interviewed David Chiswell, a pioneer in the development of therapeutic antibodies and now the CEO of Kymab, which he has the ambition to turn into the “European Genentech.” David Chiswell was, along with Greg Winter, one of the co-founders of Cambridge Antibody Technology. “We both wanted to start an antibody company,” says Chiswell. “And […]

September 18, 2017 - 4 minutesmins - By Clara Rodríguez Fernández

Infographics 21 Feb 2017

Infographic: The Biggest Biotech Company in Each European Country

We had a look into European biotech and created a map with the biggest biotech companies in each country, according to their market cap. Biotech is one of the biggest employers in Europe, where companies of all sizes strive to bring the most innovative technology to the market. To illustrate the dynamic biotech ecosystem in […]

February 21, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

vienna biotech valneva sanochemia aop pharma

News and Trends 12 Sep 2016

Grüßgott, get to Meet 9 exciting Biotechs from Vienna

Classical music, the Danube, Schnitzel, and apple strüdel – a typical combination of Vienna. The city has also been at the top of rankings for quality of life, innovation, and popular host for conferences. But what about Biotech? Once one of the most influential cities in Europe, Vienna might now be somewhat under the radar […]

September 12, 2016 - 6 minutesmins - By Denise Neves Gameiro

News and Trends 27 Sep 2015

What Happened this Week? Human Embryos Back on the Bench, Stem Cells in your Heart and New Antibiotics

Monday: Nabriva Therapeutics launched its $100M IPO on the NASDAQ to develop new antibiotics Tuesday: the Francis Crick Institute announced its application to conduct new research on human embryos Wednesday: Israeli NovoCure announced an IPO on NASDAQ with a target of €170M Thursday: Belgian TiGenix NV released the phase I results of their cardiac stem-cell therapy […]

September 27, 2015 - 1 minutemin - By Joachim Eeckhout

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us